concentrations in 57 samples were higher than in normal controls and were greater than in the matched SFs on 49 of the 57 paired samples (86%). In 18 samples CRP was absent in the SF, suggesting a local consumption or binding within the synovial membrane. Twenty four patients with RA given either sodium aurothiomalate or D-penicillamine for six months showed highly significant clinical improvements accompanied by reductions in serum and SF immunoglobulin concentrations and knee joint suprapatellar pouch synovial membrane T lymphocyte infiltrates. In this group of patients serum CRP, but not f32-microglobulin, fell significantly, but there were no significant changes in SF P2-microglobulin or CRP. These data suggest that serum and SF 32- microglobulin concentrations are not a useful index for determining the therapeutic response to sodium aurothiomalate and D-penicillamine and that serum rather than SF CRP concentrations are more helpful. The persistent raised serum and SF concentrations of P2-microglobulin probably reflect synovial inflammatory infiltrates, which are still considerable despite apparent clinical remission.
,P2-Microglobulin, a polypeptide with a molecular weight of 11-7 kD P2-microglobulin, and the results are shown in Fig. 1. There was a highly significant difference between the mean concentrations in the serum and SF (p=O-OOOl). In 25 of the 33 paired samples (76%) the 132-microglobulin concentration in the SF was higher than in the serum. On three occasions the concentrations were the same (9%), and in five the serum concentrations were higher (15%). There was a correlation between the serum and SF concentrations (r=0-50, p<0-01) (Fig. 2) .
When the patients treated with sodium aurothiomalate and D-penicillamine were examined 10 paired samples of serum and SF were available for comparison before treatment with the drugs was started. In eight of these 10 samples (80%) the SF concentration of P2-microglobulin was greater than that in the serum and on two occasions (20%) it was the same (p=0.01). After the first six months of treatment with either sodium aurothiomalate or Dpenicillamine the synovial effusion had disappeared in nine of these 24 patients.
For CRP determination 57 matched pairs of serum and SF from patients with RA were available for comparison (including all those in whom 12-microglobulin was measured), and this is illustrated in Fig. 3 patients with RA treated with a non-steroidal antiinflammatory drug when compared with normal individuals, but not when compared with patients with RA treated with gold. 5 We too have found increased concentrations of 132-microglobulin in the serum of our patients with active RA before sodium aurothiomalate or D-penicillamine treatment (mean concentrations in the patients with RA 3-9 (SD 1.9) mg/l compared with the normal range of 1-5-2-2 mg/l). The mean SF concentration of 13-microglobulin in our patients was 6-1 (2.2) mg/l, and although we have not examined the concentrations in SF from other arthritides, our results in RA SF are consistent with those published previously. In theory, it seems reasonable to speculate that if disease activity in RA is paralleled by raised tissue and blood levels of lymphocytes, and 132-microglobulin is a product of these cells, then there might be a correlation between serum or SF 13-microglobulin concentrations and synovial membrane immunohistology. Moreover, suppression of disease activity and reduced tissue lymphocyte infiltration might be associated with a concomitant fall in both serum and SF P2-microglobulin concentrations.
Manicourt et al found that in patients with RA there was a linear correlation between the SF 132-microglobulin concentrations and the 'joint count', erythrocyte sedimentation rate, latex fixation test, and the SF lymphocyte count (r=0-89, p<0-001).12 The same authors found that plasma concentrations of 132-microglobulin in RA paralleled the peripheral blood lymphocyte count and suggested that the concentrations reflected the total lymphoid mass or membrane turnover of the lymphoid tissue in RA. 1 On the other hand, Sjoblom et al found a poor correlation between serum 32-microglobulin and clinical or laboratory parameters, including Ritchie articular index, erythrocyte sedimentation rate, orosomucoid, fibrinogen, CRP, and IgG.14 Strom and Evrin studied 50 patients with active RA and found a tendency towards higher serum 2-microglobulin concentrations in the more severely affected but also a poor correlation with serum acute phase reactants.13
Rheumatoid arthritis is a disease characterised by lymphocytic proliferation within the synovial membrane and examination of Fig. 1 clearly shows that the mean concentration of 02-microglobulin was greater in SF than in serum; this was true for 25/33 (76%) of the matched pairs, pointing strongly to a local production of P2-microglobulin within the synovial membrane of inflamed joints. This is not unexpected as 132-microglobulin forms part of the HLA class I light chain and is actively produced and secreted by lymphocytes,236 which are abundant within the RA synovial membrane. Figure 2 shows the correlation between serum and SF 132-microglobulin concentrations. In view of the heavy lymphocytic infiltrate within the RA synovial membrane we postulate that this may represent diffusion of the molecule out of the synovium and into the peripheral blood. Figure 3 shows that the mean CRP concentration was greater in serum than in the SF, which might be expected as CRP is primarily produced by the liver. 16 
